BCL2 and neoplasm: While germinal center B-cell-type DLBCLs typically respond well to standard chemotherapy, this patient exhibited a high proliferation rate (Ki-67 >90%), which likely contributed to rapid tumor growth and aggressive behavior, even in the absence of a “'double-hit”' rearrangement (MYC/BCL-2), which is generally associated with poor prognosis [5].